How did CNMD's Q4 earnings surprise impact its annual performance?

CONMED's (CNMD) Q4 earnings surprise had a positive impact on its annual performance, contributing to improved financial results for 2024.

1. **Q4 Earnings Surprise**:
- CONMED reported an earnings per share (EPS) surprise of $0.13 for Q4 2024.
- This positive surprise indicates that the company's actual performance exceeded market expectations, which is generally viewed as a favorable sign by investors.

2. **Impact on Annual Performance**:
- Despite a net loss of $80.58 million in Q4 2022, the company's annual net income recovered significantly, reaching $132.42 million by Q4 2024.
- The total revenue also showed a robust increase, growing from $1.05 billion in Q4 2022 to $1.31 billion in Q4 2024.
- The improvement in earnings and revenue over the past two years suggests that the company has been able to overcome any challenges it faced, such as the earnings surprise in Q4 2022, and deliver stronger financial performance.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|CNMD|CNMD.N|CONMED|2022 Q1|51.876267748478696|1.4975E7|169|
|CNMD|CNMD.N|CONMED|2022 Q2|-1366.2979683972912|-1.68291E8|169|
|CNMD|CNMD.N|CONMED|2022 Q3|208.73695477655875|4.615E7|169|
|CNMD|CNMD.N|CONMED|2022 Q4|8.75470463099329|2.6584E7|169|
|CNMD|CNMD.N|CONMED|2023 Q1|-87.85308848080133|1819000|169|
|CNMD|CNMD.N|CONMED|2023 Q2|108.15967579965655|1.3732E7|169|
|CNMD|CNMD.N|CONMED|2023 Q3|-65.68364030335862|1.5837E7|169|
|CNMD|CNMD.N|CONMED|2023 Q4|24.401895877219378|3.3071E7|169|
|CNMD|CNMD.N|CONMED|2024 Q1|983.5074216602528|1.9709E7|169|
|CNMD|CNMD.N|CONMED|2024 Q2|118.29303815904457|2.9976E7|169|

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|CNMD|CNMD.N|CONMED|2022 Q1|4.147380273941988|2.42327E8|169|
|CNMD|CNMD.N|CONMED|2022 Q2|8.633372654911998|2.7719E8|169|
|CNMD|CNMD.N|CONMED|2022 Q3|10.553918987891185|2.75088E8|169|
|CNMD|CNMD.N|CONMED|2022 Q4|-8.432675110413548|2.50867E8|169|
|CNMD|CNMD.N|CONMED|2023 Q1|21.929458954223012|2.95468E8|169|
|CNMD|CNMD.N|CONMED|2023 Q2|14.59720769147516|3.17652E8|169|
|CNMD|CNMD.N|CONMED|2023 Q3|10.720205897749084|3.04578E8|169|
|CNMD|CNMD.N|CONMED|2023 Q4|30.36589108970092|3.27045E8|169|
|CNMD|CNMD.N|CONMED|2024 Q1|5.687587149877483|3.12273E8|169|
|CNMD|CNMD.N|CONMED|2024 Q2|4.547429262211477|3.32097E8|169|

3. **Conclusion**:
- The Q4 earnings surprise can be seen as a catalyst for CONMED's improved annual performance, demonstrating the company's ability to exceed expectations and achieve robust financial results despite previous challenges.
- Investors may view this positively, as it indicates a turnaround in the company's fortunes and potential for continued growth in the future.